{"id":"177lu-dota-eb-tate","safety":{"commonSideEffects":[{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Vomiting"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"177Lu-DOTA-EB-TATE is a radioligand therapy that targets somatostatin receptors on neuroendocrine tumors.","oneSentence":"Somatostatin receptor targeting","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:31:52.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT05475210","phase":"PHASE1","title":"177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Molecular Targeting Technologies, Inc.","startDate":"2022-06-18","conditions":"Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT03478358","phase":"PHASE1","title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":"Neuroendocrine Tumors","enrollment":60},{"nctId":"NCT03308682","phase":"PHASE1","title":"177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":"Neuroendocrine Tumors","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"177Lu-DOTA-EB-TATE","genericName":"177Lu-DOTA-EB-TATE","companyName":"Molecular Targeting Technologies, Inc.","companyId":"molecular-targeting-technologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-DOTA-EB-TATE is a treatment being studied for patients with advanced Neuroendocrine Tumors and Thyroid Cancer. It is administered as part of a clinical trial, typically in combination with an Amino Acid Solution, and may be accompanied by a 68Ga-DOTA-TATE PET Scan.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}